c.r.e.d.o. c lopidogrel for the r eduction of e vents d uring o bservation
DESCRIPTION
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial. From Steinhubl et al, JAMA 2002;228:2411-20. C.R.E.D.O. Aim of the Study. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/1.jpg)
C.R.E.D.O.Clopidogrel for the Reduction of Events
During Observation
Multicenter Multinational (USA, Canada) Prospective Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled TrialRandomized Double Blind Placebo Controlled Trial
From Steinhubl et al, JAMA 2002;228:2411-20From Steinhubl et al, JAMA 2002;228:2411-20
![Page 2: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/2.jpg)
C.R.E.D.O.Aim of the Study
Safety and efficacy of a loading dose of Safety and efficacy of a loading dose of Clopidogrel prior to elective PCIClopidogrel prior to elective PCI
Safety and efficacy of 1 Year vs 1 Month Safety and efficacy of 1 Year vs 1 Month combined treatment with Clopidogrel 75 mg + combined treatment with Clopidogrel 75 mg + ASA after elective PCIASA after elective PCI
![Page 3: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/3.jpg)
C.R.E.D.O.Inclusion Criteria
Pts with symptomatic CAD scheduled for PCI Pts with symptomatic CAD scheduled for PCI without contraindications to antithrombotic or without contraindications to antithrombotic or antiplatelet treatment or stent implantation and antiplatelet treatment or stent implantation and with no ST segment elevation within 24 hrs or with no ST segment elevation within 24 hrs or planned staged procedures or recent (<7 days) planned staged procedures or recent (<7 days) administration of GP IIb-IIIa inhibitors, administration of GP IIb-IIIa inhibitors, clopidogrel or thrombolytics clopidogrel or thrombolytics
![Page 4: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/4.jpg)
3-24 hrs before PCI3-24 hrs before PCI3-24 hrs before PCI3-24 hrs before PCI
28 Days and 1 Year Clinical Follow-Up28 Days and 1 Year Clinical Follow-Up28 Days and 1 Year Clinical Follow-Up28 Days and 1 Year Clinical Follow-Up
GP IIb-IIIa Inhib. (mainly Abciximab) on prespecified or Bail-out Indications
GP IIb-IIIa Inhib. (mainly Abciximab) on prespecified or Bail-out Indications
Clopidogrel 75 mg + ASA 325 mg for 1 Month
Clopidogrel 75 mg + ASA 325 mg for 1 Month
75 mg Clopidogrel +
ASA 325 mg for 1 Year
75 mg Clopidogrel +
ASA 325 mg for 1 Year
Placebo+
ASA 325 mg for 1 Year
Placebo+
ASA 325 mg for 1 Year
300 mg Clopidogrel Loading Dose+
ASA 325 mg
300 mg Clopidogrel Loading Dose+
ASA 325 mg
Placebo+
ASA 325 mg
Placebo+
ASA 325 mg
C.R.E.D.O.
![Page 5: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/5.jpg)
C.R.E.D.O.Outcomes
At 28 Days Death, MI, Urgent TVR in the per At 28 Days Death, MI, Urgent TVR in the per protocol population (all pts undergoing PCI) with protocol population (all pts undergoing PCI) with prespecified secondary analysis of pts receiving prespecified secondary analysis of pts receiving clopidogrel loading dose or placebo <6 hrs or clopidogrel loading dose or placebo <6 hrs or >>6 6 hrs before PCIhrs before PCI
At 1 Year Death, MI, Stroke with prespecified At 1 Year Death, MI, Stroke with prespecified secondary endpoints of TVRsecondary endpoints of TVR
![Page 6: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/6.jpg)
Power Calculation based on a Power Calculation based on a Retrospective Analysis of 2450 Pts in the EPISTENT trial: 28 Days Events
13.4%13.4%
No Ticlopidine Ticlopidine ExpectedNo Ticlopidine Ticlopidine Expected Pre-PTCA Pre-PTCA for Clopid. LoadingPre-PTCA Pre-PTCA for Clopid. Loading(expected placebo) (expected placebo) Dose + 1 Year Dose + 1 Year
7.5%7.5%8.9%8.9%
From Steinhubl et al, JACC 1998;32:1366-70From Steinhubl et al, JACC 1998;32:1366-70
C.R.E.D.O.
P<0.01P<0.01
![Page 7: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/7.jpg)
Age (yrs) 61+5 62+7 NS
Male Sex (%) 70.7% 72.1% NS
Diabetes (%) 27.5% 25.4% NS
Statins (%) 53.6% 57.5% p=0.07
Ca++ Chan. Block. (%) 25.5% 29.4% p=0.08
MI 14.3 13.1Indication (%) UAP 52.5 53.1 NS
SA 32.8 32.8
PTCA 85.6 86.2Treatment (%) Medical 8.3 7.6 NS
CABG 3.9 4.0
Clinical Characteristics (I)Clinical Characteristics (I)C.R.E.D.O.
Clopidogrel Loading Dose+ Clopidogrel 1 Year
N= 1053
Clopidogrel Loading Dose+ Clopidogrel 1 Year
N= 1053
Placebo Loading Dose+ Clopidogrel 1 Mo
N= 1063
Placebo Loading Dose+ Clopidogrel 1 Mo
N= 1063
![Page 8: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/8.jpg)
Received >1 Stent (%) 89.7 88.3 NS
Total Stent Length (mm) 24.4 23.5 NS
GP IIb-IIIa Antag. (%) 47.4% 43.3%
p=0.08
Clopidogrel Loading Dose+ Clopidogrel 1 Year
N= 900
Clopidogrel Loading Dose+ Clopidogrel 1 Year
N= 900
Placebo Loading Dose+ Clopidogrel 1 Mo
N= 915
Placebo Loading Dose+ Clopidogrel 1 Mo
N= 915
Clinical Characteristics (II)Clinical Characteristics (II)C.R.E.D.O.
![Page 9: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/9.jpg)
C.R.E.D.O.Death, MI and Urgent TVR at 28 DaysDeath, MI and Urgent TVR at 28 Days
Com
bin
e d E
nd
Po i
nt
Oc c
ur r
enc e
(%
)C
omb
ine d
En
dP
o in
t O
c cu
rre n
c e (
%)
1010
-18.5%-18.5%
Clopid. No LoadingClopid. No LoadingClopid. LoadingClopid. Loading
0 Days 7 14 21 28 0 Days 7 14 21 28 00
44
66
88
22
8.3%8.3%
6.8%6.8%
NSNS
![Page 10: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/10.jpg)
C.R.E.D.O.Death, MI and Urgent TVR at 28 DaysDeath, MI and Urgent TVR at 28 Days
Com
bin
e d E
nd
Po i
nt
Oc c
ur r
enc e
(%
)C
omb
ine d
En
dP
o in
t O
c cu
rre n
c e (
%)
1010
-38.6%-38.6%
0 Days 7 14 21 28 0 Days 7 14 21 28 00
44
66
88
22
P=0.051P=0.051
Clopid. No LoadingClopid. No LoadingClopid. < 6 Hrs LoadingClopid. < 6 Hrs LoadingClopid. Clopid. >> 6 Hrs 6 Hrs
![Page 11: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/11.jpg)
C.R.E.D.O.Death, MI, Urgent TVR at 28 DaysDeath, MI, Urgent TVR at 28 Days
![Page 12: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/12.jpg)
C.R.E.D.O.Death, MI and Stroke at 1 YearDeath, MI and Stroke at 1 Year
Com
bin
e d E
nd
Po i
nt
Oc c
ur r
enc e
(%
)C
omb
ine d
En
dP
o in
t O
c cu
rre n
c e (
%)
0 3 6 9 12 Mths 0 3 6 9 12 Mths
00
55
1010
1515
-26%-26%
Clopid. 1 MthClopid. 1 MthClopid. 1 YearClopid. 1 Year
10.5%10.5%
8.5%8.5%
P=.02P=.02
![Page 13: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/13.jpg)
C.R.E.D.O.Death, MI, Stroke at 1 Year in Key SubgroupsDeath, MI, Stroke at 1 Year in Key Subgroups
0 1/2 4 24 48 Hrs0 1/2 4 24 48 Hrs
![Page 14: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/14.jpg)
Death MI Stroke TVRDeath MI Stroke TVR
1.71.7
1 Month Clopidogrel
2.32.3
6.76.7
8.48.4
0.90.9 0.90.9
13.113.1 13.613.6
1 Year Clopidogrel1 Year Primary and Secondary Prespecified EndPoints1 Year Primary and Secondary Prespecified EndPoints
C.R.E.D.O.
![Page 15: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/15.jpg)
28 Days 1 Year28 Days 1 Year
4.84.8
1 Month Clopidogrel
P = 0.07
Loading Dose-1 Year ClopidogrelMajor BleedingsMajor Bleedings
P = 0.24
C.R.E.D.O.
3.83.8
8.88.8
6.76.7
More than ½ of major procedural bleedings due to CABGMore than ½ of major procedural bleedings due to CABG
![Page 16: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/16.jpg)
C.R.E.D.O.Conclusions
Prolongation of treatment with an ADP Prolongation of treatment with an ADP inhibitor such as clopidogrel beyond 1 month inhibitor such as clopidogrel beyond 1 month after PCIreduces the incidence of death/MI at 1 after PCIreduces the incidence of death/MI at 1 yearyear
There is a strong trend to reduction of There is a strong trend to reduction of death/MI/urgent TVR at 28 daysdeath/MI/urgent TVR at 28 days after a loading after a loading dose of 300 mg of clopidogrel administered at dose of 300 mg of clopidogrel administered at least 6 hrs before PCIleast 6 hrs before PCI
![Page 17: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/17.jpg)
C.R.E.D.O.Questions and Criticisms
Did pretreatment interfere with long-term Did pretreatment interfere with long-term results?results?
Did the poor compliance to long-term Did the poor compliance to long-term treatment with clopidogrel (only 63/61% of pts treatment with clopidogrel (only 63/61% of pts took the study drug) modify results? Can we took the study drug) modify results? Can we improve it?improve it?
Can we reduce the excess of bleeding?Can we reduce the excess of bleeding?
![Page 18: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/18.jpg)
ASA <100 mg 100-150 mg 150-300 mg >300 mgASA <100 mg 100-150 mg 150-300 mg >300 mg
Aspirin Dose and Bleeding Events in CUREAspirin Dose and Bleeding Events in CURE
1.921.92
From Peters et al EHJ 2002;Suppl.4:510From Peters et al EHJ 2002;Suppl.4:510
Aspirin/Clopidogrel (p=0.042)
2.822.822.242.24
3.193.19 3.323.32
4.634.63
3.773.77
4.644.64
Major or Life Threatening Bleeding EventsMajor or Life Threatening Bleeding Events
Aspirin Alone (p=0.057)
12563 Pts with non-ST Elevation ACS12563 Pts with non-ST Elevation ACS
![Page 19: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/19.jpg)
C.R.E.D.O.Will a higher loading dose help?Will a higher loading dose help?
0
10
20
30
40
50
60
70
80
90
300 + 75
600 + 150
10 + 10 Pts pretreated with 200 mg Aspirin10 + 10 Pts pretreated with 200 mg Aspirin
0 1/2 4 24 48 Hrs0 1/2 4 24 48 HrsAD
P 2
0 μ
mo l
- in
du
ced
Ag g
reg a
t io n
AD
P 2
0 μ
mo l
- in
du
ced
Ag g
r eg a
tion
From Muller et al, Heart 2001;85:92-93From Muller et al, Heart 2001;85:92-93
![Page 20: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/20.jpg)
C.R.E.D.O.Do we still need IIb-IIIa inhibitors in pts with Do we still need IIb-IIIa inhibitors in pts with effective clopidogrel pretreatment?effective clopidogrel pretreatment?
ISAR- REACT: after 600 mg loading dose ISAR- REACT: after 600 mg loading dose
Clopidogrel: Randomization to Abciximab or Clopidogrel: Randomization to Abciximab or
Placebo Placebo
![Page 21: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/21.jpg)
TOPSTAR StudyTOPSTAR Study
From Bonz et al, JACC 2002;40:662-8From Bonz et al, JACC 2002;40:662-8
Prior 30 min 12 Hrs 48 HrsPrior 30 min 12 Hrs 48 Hrs
100100 100100
1010
128128
1414
1081088787
9898
% P
late
let
Fu
nct
ion
% P
late
let
Fu
nct
ion
109 Pts with 375 mg Clopidogrel and 500 mg ASA 109 Pts with 375 mg Clopidogrel and 500 mg ASA 24 Hrs before PCI 24 Hrs before PCI
Placebo bolus + 18 Hrs infusionTirofiban 10 μg + 18 Hrs Infusion
![Page 22: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/22.jpg)
TOPSTAR StudyTOPSTAR Study
From Bonz et al, JACC 2002;40:662-8From Bonz et al, JACC 2002;40:662-8
Positive Troponin T (>0.01 Positive Troponin T (>0.01 μg/ml)
40%40%
63%63%
109 Pts with 375 mg Clopidogrel and 500 mg ASA 109 Pts with 375 mg Clopidogrel and 500 mg ASA 24 Hrs before PCI 24 Hrs before PCI
Placebo bolus + 18 Hrs infusionTirofiban 10 μg + 18 Hrs Infusion
![Page 23: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/23.jpg)
C.R.E.D.O.Is 1 Year Treatment Enough?Is 1 Year Treatment Enough?
CHARISMA: 15000 Stable Angina Pts with 42 Mths F-UpCHARISMA: 15000 Stable Angina Pts with 42 Mths F-Up
Dea
th, M
I K
a pla
n- M
e ier
cu
m.
Dea
th, M
I K
apla
n-M
e ie r
cu
m.
Haz
ard
rat
esH
a za r
d r
ates
From Metha et al, Lancet 2001;358:527-33From Metha et al, Lancet 2001;358:527-33
2658 Pts undergoing PCI in the CURE trial2658 Pts undergoing PCI in the CURE trial
![Page 24: C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation](https://reader033.vdocument.in/reader033/viewer/2022051517/56815050550346895dbe50ec/html5/thumbnails/24.jpg)
C.R.E.D.O.Questions and Criticisms
What about cost-effectiveness?What about cost-effectiveness?
Mechanism of clinical benefit? prevention of Mechanism of clinical benefit? prevention of periprocedural damage, TVR late events and periprocedural damage, TVR late events and non TVR late eventsnon TVR late events
Long-term treatment with clopidogrel advised Long-term treatment with clopidogrel advised for pts who receive drug eluting stents (3 mths for pts who receive drug eluting stents (3 mths SIRIUS, 6 mths TAXUS) SIRIUS, 6 mths TAXUS)